Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Mercader García, Pedro
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.contributor.author REIDAC group
• dc.date.accessioned 2021-04-29T06:32:38Z
• dc.date.issued 2021
• dc.description.abstract Background: Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC). Patients and methods: We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests. Results: One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case. Conclusion: Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable. Highlights: In 2008 methyldibromo glutaronitrile (MDBGN) was banned from cosmetics in Europe and since then, the prevalence of allergy to it has progressively decreased. Nevertheless, it is still being tested in European baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients as well as the relevance of positive patch tests in a nationwide registry (REIDAC). The frequency of allergy to MDBGN remains high, but no clinical significance was found. Most of these patients are aged >40 years and probably represent historical sensitizations.
• dc.format.mimetype application/pdf
• dc.identifier.citation Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Gimenez-Arnau AM, Ruiz-Gonzalez I et al. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study. Contact Dermatitis. 2021;85(5):572-7. DOI: 10.1111/cod.13837
• dc.identifier.doi http://dx.doi.org/10.1111/cod.13837
• dc.identifier.issn 0105-1873
• dc.identifier.uri http://hdl.handle.net/10230/47245
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Contact Dermatitis. 2021;85(5):572-7
• dc.rights This is the peer reviewed version of the following article: Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Gimenez-Arnau AM, Ruiz-Gonzalez I et al. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study. Contact Dermatitis. 2021;85(5):572-77. DOI: 10.1111/cod.13837, which has been published in final form at http://dx.doi.org/10.1111/cod.13837. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Allergic contact dermatitis
• dc.subject.keyword Clinical relevance
• dc.subject.keyword Cross-sectional study
• dc.subject.keyword Methyldibromo glutaronitrile
• dc.subject.keyword Patch tests
• dc.title Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion